This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 36
Title
Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
Short name
Graphical Representation
Point of Contact
Contributors
- Brian Chorley
- Michelle Angrish
- Lyle Burgoon
Coaches
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
1.29 |
This AOP was last modified on April 29, 2023 16:02
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Decreased, PPAR-alpha activation | September 16, 2017 10:14 |
Decreased, PPAR-beta activation | September 16, 2017 10:14 |
Decreased, PPAR-gamma activation | October 30, 2023 09:07 |
Accumulation, Fatty acid | September 16, 2017 10:14 |
Decreased, HSD17B10 expression | September 16, 2017 10:14 |
Decreased, Mitochondrial fatty acid beta-oxidation | September 16, 2017 10:14 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | September 16, 2017 10:14 |
Increased, Liver Steatosis | May 21, 2024 10:00 |
Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid | December 03, 2016 16:37 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation | December 03, 2016 16:37 |
Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | December 03, 2016 16:37 |
Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Accumulation, Fatty acid leads to Increased, Liver Steatosis | December 03, 2016 16:37 |
Abstract
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 231 | Decreased, PPAR-alpha activation | Decreased, PPAR-alpha activation |
MIE | 232 | Decreased, PPAR-beta activation | Decreased, PPAR-beta activation |
MIE | 233 | Decreased, PPAR-gamma activation | Decreased, PPAR-gamma activation |
KE | 327 | Accumulation, Fatty acid | Accumulation, Fatty acid |
KE | 140 | Decreased, HSD17B10 expression | Decreased, HSD17B10 expression |
KE | 179 | Decreased, Mitochondrial fatty acid beta-oxidation | Decreased, Mitochondrial fatty acid beta-oxidation |
KE | 8 | Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
AO | 459 | Increased, Liver Steatosis | Increased, Liver Steatosis |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Overall Assessment of the AOP
Consider the following criteria (may include references to KE Relationship pages): 1. concordance of dose-response relationships; 2. temporal concordance among the key events and adverse effect; 3. strength, consistency, and specificity of association of adverse effect and initiating event; 4. biological plausibility, coherence, and consistency of the experimental evidence; 5. alternative mechanisms that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP; 6. uncertainties, inconsistencies and data gaps.